Egalet Corporation has announced that the FDA has approved Arymo ER (morphine sulfate) extended-release (ER) tablets C-II for the management...
Egalet Corporation announced that the FDA has accepted the new drug application (NDA) for Arymo ER (morphine sulfate) extended-release tablets....
Egalet Corporation announced that the joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and...
Egalet Corporation has announced the company has submitted a new drug application (NDA) for Arymo ER (morphine sulfate) extended-release tablets...
Egalet announced that results from a Category 3 oral human abuse potential (HAP) study and a Category 3 intranasal HAP...
FDA issues tentative approval for expanded label for Arymo ER with abuse-deterrent properties for treatment of chronic pain
The FDA has approved MorphaBond (morphine sulfate extended-release) tablets, for oral use, from Inspirion Delivery Technologies. MorphaBond is an abuse-deterrent...